STERIS (STE) Stock Price, News & Analysis

Company Overview

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, surgical procedures, and the manufacture of healthcare and pharmaceutical products. The company serves healthcare providers, pharmaceutical and biotechnology manufacturers, and other organizations that require controlled, sterile environments.

Its Healthcare segment offers sterilization and decontamination equipment, operating-room products, surgical instruments, endoscopy products, consumables, and related maintenance and procedural services. STERIS also provides contract sterilization and laboratory services through its Applied Sterilization Technologies business, while its Life Sciences operations supply equipment, consumables, and services for pharmaceutical and biopharmaceutical production, cleanrooms, and research facilities.

Founded in 1987, STERIS has expanded through organic development and acquisitions and serves customers across North America, Europe, Asia-Pacific, and other international markets. The company is headquartered in Mentor, Ohio. Dan Carestia serves as STERIS’s president and chief executive officer.

Key Stats

• Today's Range: $216.14 to $221.45
• 50-Day Range: $205.14 to $238.93
• 52-Week Range: $195.14 to $269.44
• Volume: 509,887 shs
• Average Volume: 690,844 shs
• Market Capitalization: $21.22 billion
• P/E Ratio: 26.61
• Dividend Yield: 1.27%
• Price Target: $271.33
• Consensus Rating: Moderate Buy

STERIS Stock Analysis - MarketRank™

STERIS scored higher than 95% of companies evaluated by MarketBeat, and ranked 13th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

STERIS has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

STERIS has a consensus price target of $271.33, representing about 24.7% upside from its current price of $217.66.

Amount of Analyst Coverage

STERIS has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.25%

Earnings Growth

Earnings for STERIS are expected to grow by 10.25% in the coming year, from $11.12 to $12.26 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of STERIS is 26.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of STERIS is 26.61, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 200.71.

Price to Book Value per Share Ratio

STERIS has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.96% of the float of STERIS has been sold short.

Short Interest Ratio / Days to Cover

STERIS has a short interest ratio ("days to cover") of 4.15.

Change versus previous month

Short interest in STERIS has recently increased by 2.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

STERIS pays a meaningful dividend of 1.26%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

STERIS has been increasing its dividend for 20 years.

Dividend Coverage

The dividend payout ratio of STERIS is 33.74%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, STERIS will have a dividend payout ratio of 22.51% next year. This indicates that STERIS will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.29

News Sentiment

STERIS has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for STERIS this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for STE on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added STERIS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, STERIS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $956,795.00 in company stock.

Percentage Held by Insiders

1.12% of the stock of STERIS is held by insiders.

Percentage Held by Institutions

94.69% of the stock of STERIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Record date for 9/25 Dividend: 9/04/2026
• Ex-Dividend for 9/25 Dividend: 9/04/2026
• Dividend Payable: 9/25/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:STE
• CIK: 1757898
• Web: www.steris.com
• Phone: +35312322000
• Fax: 440-639-4457
• Employees: 17,937
• Year Founded: 1985

Price Target and Rating

• Average Price Target for STERIS: $271.33
• High Price Target: $275.00
• Low Price Target: $269.00
• Potential Upside/Downside: +24.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.18
• Trailing P/E Ratio: 26.61
• Forward P/E Ratio: 19.57
• P/E Growth: N/A
• Net Income: $782.30 million
• Net Margins: 13.34%
• Pretax Margin: 18.03%
• Return on Equity: 14.34%
• Return on Assets: 9.66%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.91
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $5.94 billion
• Price / Sales: 3.58
• Cash Flow: $15.10 per share
• Price / Cash Flow: 14.41
• Book Value: $73.39 per share
• Price / Book: 2.97

Miscellaneous

• Outstanding Shares: 97,500,000
• Free Float: 96,408,000
• Market Cap: $21.22 billion
• Optionable: Optionable
• Beta: 0.92